Life Science REIT (LABS) Share Price, News & Analysis

Company Overview

Life Science REIT plc (the Company) is a closed-ended Real Estate Investment Trust (REIT) incorporated in England and Wales on 27 July 2021. The Company began trading on 19 November 2021 and its shares are admitted to trading on the Premium Listing Segment of the Main Market of the London Stock Exchange. The registered office of the Company is located at 6th Floor, 65 Gresham Street, London, EC2V 7NQ.

Key Stats

• Today's Range: 34.50 to 35.70
• 50-Day Range: 32.80 to 39
• 52-Week Range: 31.30 to 47.75
• Volume: 434,742 shs
• Average Volume: 686,317 shs
• Market Capitalization: £126.75 million
• P/E Ratio: N/A
• Dividend Yield: 5.60%
• Price Target: GBX 46.50
• Consensus Rating: Moderate Buy

Life Science REIT Stock Analysis - MarketRank™

Life Science REIT scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Life Science REIT has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Life Science REIT has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Life Science REIT is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Life Science REIT is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Life Science REIT has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for LABS.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Life Science REIT is a leading dividend payer. It pays a dividend yield of 5.67%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Life Science REIT does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for LABS.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Life Science REIT this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Life Science REIT insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.96% of the stock of Life Science REIT is held by insiders.

Percentage Held by Institutions

67.27% of the stock of Life Science REIT is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LABS Stock Analysis - Frequently Asked Questions

How have LABS shares performed this year?

Life Science REIT's stock was trading at GBX 38 at the beginning of the year. Since then, LABS stock has decreased by 6.1% and is now trading at GBX 35.70.
View the best growth stocks for 2025 here.

How do I buy shares of Life Science REIT?

Shares of LABS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Real Estate
• Industry: REIT - Healthcare Facilities
• Sub-Industry: N/A
• Current Symbol: LON:LABS
• CUSIP: N/A
• CIK: N/A
• Web: www.lifesciencereit.co.uk
• Phone: 44-20-7945-9566
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 46.50
• High Stock Price Target: GBX 57
• Low Stock Price Target: GBX 36
• Potential Upside/Downside: +30.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (11.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-40,615,287.36
• Net Margins: -198.99%
• Pretax Margin: N/A
• Return on Equity: -14.53%
• Return on Assets: 1.25%

Debt

• Debt-to-Equity Ratio: 44.18
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: £20.41 million
• Price / Sales: 6.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 76.35 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 355,028,736
• Free Float: N/A
• Market Cap: £126.75 million
• Optionable: Not Optionable
• Beta: 0.08